|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial chemoembolization using 40 μm drug eluting beads for hepatocellular carcinoma显示文摘AIM To assess the safety and efficacy of transarterial chemoembolization(TACE) of hepatocellular carcinoma(HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment.METHODS Drug eluting bead TACE(DEB-TACE) using a new generation of microspheres(embozene tandem,40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensatedcirrhosis.Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors(RECIST) and modified RECIST(m RECIST) guidelines applied to computed tomography or magnetic resonance imaging.Eleven out of the 48 treated patients treated progressed on to receive liver orthotopic transplantation(OLT).This allowed for histological analysis on the treated explanted nodules.RESULTS DEB-TACE with 40 μm showed a good safety profile without major complications or 30-d mortality.The objective response rate of treated tumors was 72.6% and 26.7% according to m RECIST and RECIST respectively.Histological examination in 11 patients assigned to OLT showed a necrosis degree > 90% in 78.6% of cases.The overall time to progression was 13 mo(11-21).CONCLUSION DEB-TACE with 40 μm particles is an effective treatment for the treatment of HCC in early-intermediate patients(Barcelona Clinic Liver Cancer stage A/B) with a good safety profile and good results in term of objective response rate and necrosis. | Giorgio Greco Tommaso Cascella Antonio Facciorusso Roberto Nani Rodolfo Lanocita Carlo Morosi Marta Vaiani Giuseppina Calareso Francesca G Greco Antonio Ragnanese Marco A Bongini Alfonso V Marchianò Vincenzo Mazzaferro Carlo Spreafico | 2017 | World Journal of Radiology2017，9，5： | 3 |
| 2 | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study<.-- Doctopic: TAS -->显示文摘 | Carlo Sposito Luigi Mariani Alessandro Germini Maria Flores Reyes Marco Bongini Glenda Grossi Sherrie Bhoori Vincenzo Mazzaferro | 2013 | Journal of Hepatology2013，，1： | 3 |
| 3 | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study显示文摘 | Carlo Sposito Luigi Mariani Alessandro Germini Maria Flores Reyes Marco Bongini Glenda Grossi Sherrie Bhoori Vincenzo Mazzaferro | 2013 | Journal of Hepatology2013，，1： | 2 |
| 4 | Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study显示文摘 | Vincenzo Mazzaferro Carlo Sposito Sherrie Bhoori Raffaele Romito Carlo Chiesa Carlo Morosi Marco Maccauro Alfonso Marchianò Marco Bongini Rodolfo Lanocita Enrico Civelli Emilio Bombardieri Tiziana Camerini Carlo Spreafico | 2013 | Hepatology2013，，： | 2 |
| 5 | Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatisis显示文摘 | Di-stefano G Colonna FP Bongini A | 1997 | Bichem Pharmacol1997，54，3： | 1 |
| 6 | Ribavirin conjugated with lactosaminated poly-L-lysine:selective delivery to the liver and increased antiviral activity in mice with viral hepatitis显示文摘 | Di Stefano G Colonna FP Bongini A | 1997 | Biochem Pharmacol1997，54，3： | 1 |
| 7 | Ribavirin conjugated with lactosaminated poly-L-lysine, selective delivery to the liver and increased antiviral activity in mice with viral hepatitis 显示文摘 | Di Stefano G Colonna F P Bongini A | 1997 | Biochemical Pharmacology1997，54，： | 1 |
| 8 | Turning Muller glia into neural progenitorsin the retina显示文摘 | Fischer AJ Bongini R | 2010 | Mol Neurobiol2010，42，3： | 1 |
| 9 | How good is the market at assessing bank fragility? A horse race between different indicators显示文摘 | Paola Bongini Luc Laeven Giovanni Majnoni | 2002 | Journal of Banking and Finance2002，，5： | 1 |
| 10 | How good is the market at assessing the bank fragility?A horse race between different indicators显示文摘 | Paola Bongini Luc Laeven Giovanni Majnoni | 2002 | Journal of banking&Finance2002，5，26： | 1 |
| 11 | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study<!-- Doctopic: TAS -->显示文摘 | Carlo Sposito Luigi Mariani Alessandro Germini Maria Flores Reyes Marco Bongini Glenda Grossi Sherrie Bhoori Vincenzo Mazzaferro | 2013 | Journal of Hepatology2013，，1： | 1 |
| 12 | Identifying and Regulating Systemically Important Financial Institutions 显示文摘 | Paola Bongini Laura Lieri | 2014 | Eco- nomic Notes by Banca Monte dei Paschi di Siena SPA2014，43，12014： | 1 |
| 13 | Ribavirin conjugated with lactosaminated poly-L-lysine:selective delivery to the liver and increased antiviral activity in mice with viral hepatitis显示文摘 | Colona FP Bongini A | 1997 | Biochem Pharmacol1997，54，3： | 1 |
| 14 | Drug‐eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma显示文摘 | Antonio Facciorusso Luigi Mariani Carlo Sposito Carlo Spreafico Marco Bongini Carlo Morosi Tommaso Cascella Alfonso Marchianò Tiziana Camerini Sherrie Bhoori Federica Brunero Michele Barone Vincenzo Mazzaferro | 2016 | Journal of Gastroenterology and Hepatology2016，，3： | 1 |
| 15 | How good is the market at assessing bank fragility? A horse race between different indicators 显示文摘 | Bongini P Laeven L Majnoni G | 2002 | Journal of Banking & Finance2002，26，： | 1 |
| 16 | Development of a prognostic scoring system for resectable hepatocellular carcinoma显示文摘AIM To develop a prognostic scoring system for overall survival(OS) of patients undergoing liver resection(LR) for hepatocellular carcinoma(HCC).METHODS Consecutive patients who underwent curative LR for HCC between 2000 and 2013 were identified. The series was randomly divided into a training and a validation set. A multivariable Cox model for OS was fitted to the training set. The beta coefficients derived from the Cox model were used to define a prognostic scoring system for OS. The survival stratification was then tested, and the prognostic scoring system was compared with the European Association for the Study of the Liver(EASL)/American Association for the Study of Liver Diseases(AASLD) surgical criteria by means of Harrell's C statistics.RESULTS A total of 917 patients were considered. Five variables independently correlated with post-LR survival: Model for End-stage Liver Disease score, hepatitis C virus infection, number of nodules, largest diameter and vascular invasion. Three risk classes were identified, and OS for the three risk classes was significantly different both in the training(P < 0.0001) and the validation set(P = 0.0002). Overall, 69.4% of patients were in the low-risk class, whereas only 37.8% were eligible to surgery according to EASL/AASLD. Survival of patients in the low-risk class was not significantly different compared with surgical indication for EASL/AASLD guidelines(77.2 mo vs 82.5 mo respectively, P = 0.22). Comparison of Harrell's C statistics revealed no significant difference in predictive power between the two systems(-0.00999, P = 0.667).CONCLUSION This study established a new prognostic scoring system that may stratify HCC patients suitable for surgery, expanding surgical eligibility with respect to EASL/AASLD criteria with no harm on survival. | Carlo Sposito Stefano Di Sandro Federica Brunero Vincenzo Buscemi Carlo Battiston Andrea Lauterio Marco Bongini Luciano De Carlis Vincenzo Mazzaferro | 2016 | World Journal of Gastroenterology2016，22，36： | 1 |
| 17 | Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients显示文摘AIM To investigate death for liver failure and for tumor recurrence as competing events after hepatectomy of hepatocellular carcinoma.METHODS Data from 864 cirrhotic Child-Pugh class A consecutive patients, submitted to curative hepatectomy(1997-2013) at two tertiary referral hospitals, were used for competing-risk analysis through the Fine and Gray method, aimed at assessing in which circumstances the oncological benefit from tumour removal is greater than the risk of dying from hepatic decompensation. To accomplish this task, the average risk of these two competing events, over 5 years of follow-up, was calculated through the integral of each cumulative incidence function, and represented the main comparison parameter. RESULTS Within a median follow-up of 5.6 years, death was attributable to tumor recurrence in 63.5%, and to liver failure in 21.2% of cases. In the first 16 mo, the risk of dying due to liver failure exceeded that of dying due to tumor relapse. Tumor stage only affects death from recurrence; whereas hepatitis C infection, Model for End-stage Liver Disease score, extent of hepatectomy and portal hypertension influence death from liver failure(P < 0.05 in all cases). The combination of these clinical and tumoral features identifies those patients in whom the risk of dying from liver failure did not exceed the tumour-related mortality, representing optimal surgical candidates. It also identifies those clinical circumstances where the oncological benefit would be borderline or even where the surgery would be harmful. CONCLUSION Having knowledge of these competing events can be used to weigh the risks and benefits of hepatic resection in each clinical circumstance, separating optimal from non-optimal surgical candidates. | Alessandro Cucchetti Carlo Sposito Antonio Daniele Pinna Davide Citterio Matteo CesconMarco Bongini Giorgio Ercolani Christian Cotsoglou Lorenzo Maroni Vincenzo Mazzaferro | 2017 | World Journal of Gastroenterology2017，23，8： | 1 |
| 18 | Convergent synthesis of cis a, Q-epoxy carboxylic acids from l-halo-2 trimethylsilyloxy-3-aza 4 phenyl-1, 3-butadiene 显示文摘 | Panunzio M Bongini A Monari M | 2004 | Tetrahedron2004，60，83： | 1 |
| 19 | Chest fast MRI: an imaging alternative on pre-operative evaluation of Pectus Excavatum显示文摘 | Lo Piccolo R Bongini U ? Basile Mv | 2012 | J Peduatr Surg2012，47，3： | 1 |
| 20 | Turning Muller glia into neural progeni-tors in the retina显示文摘 | Fischer AJ Bongini H | 2010 | Mol Neurobiol2010，42，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员